---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-113561"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:49:43.952766+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OS Therapies announces $6M private placement; OST-HER2 Phase 2b data in Jan 2025

## Summary
- Gross proceeds of $6M from sale of 1.5M units at $4.00/unit; each unit = 1 share Series A convertible preferred + 1 warrant.
- Initial conversion price $4.00, warrant exercise price $4.40; prices subject to reset with floor of $1.00 and ceiling $4.00.
- Proceeds to fund working capital and support commercialization of OST-HER2 for recurrent metastatic osteosarcoma.
- Phase 2b trial data for OST-HER2 expected during week of JP Morgan Healthcare Conference in January 2025.
- 95% of investment from pre-IPO and/or IPO investors; $6M provides cash runway into 2026.

## SEC filing metadata
- accession: 0001213900-24-113561
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/0001213900-24-113561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea0226258-8k_osthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-113561
- JSON: https://secwatch.observer/filing/0001213900-24-113561.json
- Plain text: https://secwatch.observer/filing/0001213900-24-113561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.